PQ Bypass reports positive results for Detour system in patients with long femoropopliteal blockages

114

A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour system for treating long-segment (>25cm) blockages in the femoropopliteal artery. The data were presented as a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA; 11-14 September, Las Vegas, USA) by Sean Lyden (Cleveland Clinic, Cleveland, USA).

With peripheral artery disease (PAD), extremely long blockages, such as those greater than 20cm, are challenging to treat. Historically, physicians have treated these blockages with open bypass surgery, which has the benefit of durability; however, it is associated with an increased risk of complications, longer hospital stays and prolonged rehabilitation. Minimally invasive approaches to PAD, including angioplasty and stenting, work very well on shorter blockages; however, they have not been as effective on longer ones.

“Patients with long segment femoropopliteal blockages are in need of advanced therapeutic alternatives to existing treatments. While endovascular revascularisation is effective in shorter lesions, its durability in longer segment blockages has not matched that of open surgery. Fully percutaneous bypass is designed to combine the durability advantages of surgical bypass with the minimally invasive advantages of a percutaneous procedure,” said Lyden. “The outcomes we are seeing in the DETOUR I trial indicate that a fully percutaneous bypass procedure has potential to fill this gap in treatment options.”

The analysis of a subset of the DETOUR I study presented at VIVA is one of the largest prospective series ever to evaluate the percutaneous treatment of femoropopliteal blockages with lengths of 25-45 cm (mean of 33.8cm). The six-month outcomes from 50 patients demonstrated the Detour system’s ability to successfully treat these long blockages without significant impact on venous health and low rates of major adverse events (MAEs). The results included:

  • Primary safety endpoint: 2% MAEs – defined as death, target vessel revascularisation (TVR) or amputation at 30 days. There were no deaths or amputations and one TVR;
  • Primary patency of 88.9% at six months with optimal placement; overall primary patency of 76.9%;
  • Successful delivery of devices to the identified area and removal of the delivery system in 100% of lesions (53);
  • Improvement in Rutherford class of at least 2 grades in 92% of patients (45/49);
  • Significant improvement in ankle brachial index from 0.64±0.17 to 0.92±0.14 (p<0.0001);
  • No impact on venous function; no device-related deep vein thrombosis in treated vessels.

Percutaneous femoropopliteal bypass (the Detour procedure) is a newly developed procedure that utilises PQ Bypass’ proprietary Detour system technologies (Torus stent graft, Detour crossing device and Detour snare) to provide fully percutaneous bypass of long-segment blockages in the femoropopliteal artery. The Detour procedure creates a pathway around a lesion by placing stent grafts that cross from the superficial femoral artery into the femoral vein and back into the artery. The new path through the stent grafts re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient.

(Visited 63 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here